ALLO – allogene therapeutics, inc. (US:NASDAQ)

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies [Seeking Alpha]

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript [Seeking Alpha]

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Citigroup Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $14.00 price target on the stock, down previously from $17.00.

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2 [Yahoo! Finance]

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $11.00 price target on the stock.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $35.00 to $14.00. They now have a "buy" rating on the stock.

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update [Yahoo! Finance]

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform [Yahoo! Finance]

Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T-cell therapy to boost the market growth, Technavio [Yahoo! Finance]

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock? [Yahoo! Finance]

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse [Yahoo! Finance]

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse